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ABSTRACT
The increasing use of illicit drugs imposes a public health challenge worldwide. People who 
inject drugs (PWID) are more susceptible to health complications due to immunosuppression 
associated with drug use and non-hygienic self-administration of substances, contaminants, 
and liquids. PWID are subjected to increased risk of acquiring and transmitting different 
pathogens (frequently functioning as sentinel cases for (re)emerging pathogens), including 
those transmitted by arthropods and vertebrate reservoirs in unhealthy environments. A 
clear association between injection drug use and HIV, HBV, and HCV infections has been 
described; however, other infectious viral and bacterial agents have been seldomly assessed. 
In this study, we investigated the seroprevalence of Bartonella spp., Coxiella burnetii, and 
Hantavirus among 300 randomly selected PWIDs from Rio de Janeiro, as part of a multi-city 
cross-sectional study carried out in the 1990s. Point seroprevalences and respective 95% CIs 
are as follows: 9.3% for C. burnetii (95% CI: 6.0%-13.0%), 1.0% for Bartonella spp. (95% 
CI: 0.0%-3.0%), and 4.0% for Hantavirus (95% CI: 2.0%-7.0%). In addition to the blood-
borne pathogens, the results of this study increase our knowledge on other transmissible 
infectious agents in PWID. The high seroprevalence of C. burnetii and Hantavirus found 
among PWID is intriguing and suggests the need to carry out prospective studies, including 
molecular analyses, to confirm these findings and allow a better understanding of the putative 
relevance of these zoonotic infectious agents among PWID.
KEYWORDS: PWID (Persons who inject drugs). Intravenous drug user. Emergent infections. 
Bartonella spp. Coxiella burnetii. Hantavirus.
INTRODUCTION
Drug abuse is increasing worldwide, with approximately 87,000 associated 
deaths reported in 20141. According to the World Drug Report1, there are more than 
12 million People Who Inject Drugs (PWID) in the population aged 15-64 years old 
(a prevalence of 0.27%; 0.19%-0.48%) worldwide, predominantly in Eastern and 
Central Europe, as well as in certain areas of Southeast and Central Asia2. In these 
regions, the rate of injection drug use is 4.6 times higher than the world average1. 
The implementation of measures to reduce drug-related harm, such as syringe 
exchange programs providing sterile syringes to PWIDs, condom distribution, 
hepatitis B virus (HBV) vaccination and treatment, have significantly decreased 
new HIV and hepatitis cases among PWID3 leading to a substantial decline in the 
number of new AIDS cases in this population between 2002 and 2016 according 
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to the Brazilian Ministry of Health4. A decrease in the 
frequency of HBV and hepatitis C virus (HCV) infections in 
PWID has also been described5-7. Altogether, these figures 
reinforce the success of harm reduction policies and the 
need to maintain and refocus them, considering the most 
at-risk subgroups and contexts.
Injection drug abuse usually takes place in scenarios of 
poor sanitation, with the presence of rodents, arthropods 
and vertebrate reservoirs for different zoonotic pathogens, 
in such a way that intravenous/subcutaneous (“skin 
popping”) administration of non-sterile substances and 
syringe/needle sharing favor the recurring transmission of 
viral and bacterial infections8. Besides the most-frequently 
assessed infectious diseases in PWID, including HIV 
and hepatitis, other emerging and re-emerging infectious 
diseases prevalent among PWID, including tetanus, 
visceral leishmaniasis, and malaria, should be investigated 
and properly managed9-12. The injection of illicit drugs is 
important as an ecological niche and route for the worldwide 
diffusion of emerging blood-borne pathogens. Many PWID 
travel widely, including internationally. The international 
diffusion of PWID includes spreading pathogens to 
geographically different areas, leading to contact with 
reservoirs for emerging diseases. Infective endocarditis 
is another important and serious, potentially short-term 
lethal medical condition among PWID, and can be acquired 
through direct injection of the bacteria (Staphylococcus) or 
through secondary spread, via skin and soft tissue abscesses, 
into the bloodstream13-15.
Studies on C. burnetii, Bartonella, and Hantavirus 
infections among PWID are still scarce8,16-25 and are totally 
unavailable in Brazilian drug use scenarios. 
Coxiella burnetii, the causative agent of Q fever, is 
transmitted to both humans and animals by the inhalation of 
aerosols or contaminated excreta such as milk, feces, urine, 
saliva and conception products (placenta, vaginal secretions, 
and amniotic fluid samples), derived from infected animals. 
Ticks are suspected of having a role in the transmission of 
the bacteria among wild vertebrates26. In Brazil, despite 
the existence of serologic evidence of Q fever since the 
1950s, reports of this zoonosis have been rare, considering 
a timespan of almost seven decades27-34. 
Bartonella spp. are intracellular hemotropic bacteria that 
grow fastidiously, transmitted by flea, lice and ticks bites 
in a range of mammalian hosts, including rodents, cats, 
dogs, humans, and bats35,36. These proteobacteria can be 
transmitted directly from a cat to humans during a scratch 
and less often by the bite of infected fleas in the case of 
Bartonella henselae. In Brazil, little information is available 
about the diversity of Bartonella. At present, B. henselae, B. 
quintana, B. clarridgeiae, B. vinsonii subsp. berkhoffii, and 
B. vinsonii subsp. arupensis have been detected in human 
and animal populations37-43. 
Hantaviruses are spherical, enveloped RNA viruses 
classified into the Bunyaviridae family and are known to 
cause Hemorrhagic Fever with Renal Syndrome (HFRS) in 
Eurasia and Hantavirus Pulmonary Syndrome (HPS) in the 
American continent44,45. Human infection occurs by aerosol 
droplet of infected excrements or contact with contaminated 
rodent secretions46. In Brazil, HPS is an important public 
health issue and cases have been associated with six 
different genotypes - Anajatuba, Araraquara, Castelo dos 
Sonhos, Juquitiba, Laguna Negra, and Rio Mamore. Other 
hantaviruses - Jabora, Rio Mearim, and Seoul - were also 
detected in rodents, but have not yet been associated with 
HPS/HFRS44,45. 
We investigated the prevalence of C. burnetii, Bartonella, 
and Hantavirus infections among 300 PWID, previously 
assessed by a cross-sectional multicity study conducted in 
Rio de Janeiro and two other sites in Brazil during 1999-
20016. 
This information is valuable to warn policymakers 
and health professionals about infections that have been 
neglected by policies and initiatives that aimed to reduce 
drug-related harms and curb their spread. 
MATERIALS AND METHODS
PWID
This is a retrospective assessment of a subsample 
from a cross-sectional multicity study conducted from 
1999-2001. PWID were assessed in “drug scenarios” 
(public places, nightclubs and bars) of Rio de Janeiro, 
Brazil. The targeted communities were defined after a 
comprehensive effort of interviewing key informants and 
mapping drug scenarios from different communities using 
a brief ethnographic assessment, in-depth interviews, and 
focus groups, according to the World Health Organization 
(WHO) guidelines, after Watters and Biernacki’s original 
contribution on targeted sampling procedures. New 
sampling methods that have been used in recent studies, 
such as respondent-driven sampling or time-location 
sampling, were virtually ignored in Brazil in that period 
and were introduced much later47.
The original database belongs to a large multicity study 
conducted in 13 cities, worldwide, entitled “Multicenter 
study of WHO-II, Brazil. Epidemiological survey - risk 
of HIV infection and viral hepatitis among drug users and 
transitions of cocaine use routes” under the coordination 
of Dr. Francisco I. Bastos and developed in the 1990s; this 
database was used in the present study for the analysis of 
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a core set of original variables. A total of 300 biological 
samples, out of the existing 608 samples, were randomly 
selected with the help of the Epidemiological calculator 
(Epicalc R) version 2.15.1.0, taking into account the 
constraints secondary to high-cost laboratory inputs, as 
well as the necessary statistical power to carry out simple 
statistical tests for contingency tables. 
Ethics Statement
The study was approved by the Institutional Review 
Board (IRB) of the Fundação Oswaldo Cruz (FIOCRUZ) 
after addition of tests for Bartonella spp, Coxiella burnetii, 
and Hantavirus infection (amendment). In accordance with 
ethical guidelines defined by National Commission for 
Research Ethics (CONEP), and international norms under 
the aegis of WHO regulations. Formal written consent 
forms were obtained from each adult individual (none of 
the participants were children; > 18 years old – Brazilian 
national adult legal age), who was interviewed using a 
standardized questionnaire that included questions about 
socio-demographic status, pattern of injection drug use 
and sexual behavior. 
Characterization of Coxiella, Bartonella, and 
Hantavirus infections
The presence of immunoglobulin G antibodies 
(IgG) against Coxiella burnetii and Bartonella spp. was 
determined by the indirect immunofluorescence assay 
(IFA), using commercial kits from ScimedX® (Dover, NJ, 
USA) and BION Enterprises® (Des Plaines, IL, USA), 
respectively48,49, in accordance with the manufacturer´s 
instructions. Serum samples were screened at a 1:64 dilution 
and samples positive at 1:64 were further diluted and tested 
by IFA to determine the end titers. Negative and positive 
controls were included for each test run.
For Hantavirus investigation, IgG-ELISA was 
performed using a recombinant nucleocapsid protein 
from the Araraquara virus as the antigen, according to 
the protocol described by Figueiredo et al.50. Serum 
samples were screened at a 1:400 dilution and the sample 
was considered positive when the optical density (OD) 
was higher than 0.3. Negative and positive controls were 
included for each test run. 
Statistical analysis
Statistical analysis was conducted with the help 
of Microsoft Office Professional Plus 2010 - Excel. 
Contingency table analysis (e.g., chi-square or Fisher’s 
exact test and Student’s t-test for means) were employed. 
Results were considered significant when P<0.05.
Associations between the results of the serological tests 
and demographic (sex, ethnicity, education and place of 
residence) parameters as well as drug use variables (date 
of the first drug use, first injection, use of a previously used 
syringes and location where drug use took place) were 
analyzed in bivariate analyses. 
RESULTS
The socio-demographic and drug use patterns of the 300 
PWID included in the study are shown in Table 1. The mean 
age was 31.7 ± 10 years (range 16-68 years). 
The average number of years of formal education was 
9.4 ± 4.2 years (range 0-29 years): 2.3% had no schooling 
at all, 52% had not completed the 1st grade, 18% had 
completed the 1st grade, 10.3% had not completed high 
school, 11% had completed high school and 6.3% had 
college degree.
Table 1 - Socio-demographic and drug use patterns in the 
population of people who inject drug (PWID), Rio de Janeiro, 
Brazil (1999-2001)
Variables
Study population 
(300) 
n (%)
Gender Male Female
280 (93.3) 
20 (6.7)
Age
<20 
20-29 
30-39 
40-49 
>49
27 (9.0) 
119 (39.7) 
83 (27.7) 
58 (19.3) 
13 (4.3)
Marital status
Single 
Living as married 
Legally married 
Legally separated 
Divorced 
Widowed
187 (62.3) 
50 (16.7) 
34 (11.3) 
19 (6.3) 
6 (2.0) 
4 (1.3)
Formal 
education 
(years)
0 
1-8 
9-12 
>12
7 (2.3) 
130 (43.3) 
108 (36.0) 
55 (18.3)
How many times 
injected in life
Once 
2-9 times  
10-99 times 
100-999 times 
1000 or more times
10 (3.3) 
59 (19.7) 
115 (38.3) 
108 (36.0) 
8 (2.7)
How long 
without 
injecting 
(months)
0 
1-11 
12-24 
>24
69 (23.0) 
92 (30.7) 
53 (17.7) 
86 (28.7)
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Regarding the level of education of the head of the 
family: 23% were illiterate or studied until the the 5th grade; 
36.7% studied beyond the 5th grade, but did not complete the 
elementary school; 19.7% concluded the elementary school; 
16.7% had completed high school; 2.7% had completed 
higher education and in 1.3% there was no information 
about the education level of the head of the family.
Most subjects (66.0%) did not report any treatment 
for chemical dependency. Among those who had been 
previously treated for drug abuse (34.0%), 39 were 
submitted to more than one treatment schedule. The most 
frequently reported approaches were admission to drug 
treatment clinics (49.7%), support from mutual aid groups 
(18.6%) and support from religious institutions (8.6%). 
Overall, 44.7% (n=134) of the sampled PWID had been 
imprisoned at some point; among those, incarceration 
occurred once among 56% of the interviewees, twice among 
20.9%, three times among 17.9%, and more than three 
times among 5.2%. Among those arrested, 23.1% injected 
drugs inside jails/prisons, and 71% injected drugs with a 
previously used needle/syringe.
About half of the sampled PWID (53.7%) started 
consuming drugs before they were 17 years old and the 
majority (78.0%) reported using marijuana or hashish in 
the six months before the interview. 
At the time of the study admission, the main route 
of drug use was: (i) non-injectable by 87.0% of the 
interviewees, (ii) injectable by 5.7%, (iii) both routes by 
4.3%, and (iv) 3.0% refused to answer. A total of 23.0% 
had injected drugs in the month before the survey, 30.7% 
did not inject drugs for more than a month and less than a 
year before the survey and 46.3% did not inject drugs for 
more than one year.
PWID and anti-Coxiella burnetii antibodies 
Point seroprevalence for C. burnetii was 9.3% (28/300) 
(95% CI: 6.0%-13.0%). There were no statistically 
significant associations between the demographic or 
behavioral data and this biological outcome. 
PWID characteristics and anti-Bartonella spp. 
antibodies
Point seroprevalence for anti-Bartonella spp. was 
1.0% (3/300) (95% CI: 0%-3.0%). All individuals were 
male, with incomplete elementary educationand did not 
report treatment for chemical dependency. At the time they 
were interviewed, two individuals reported previous non-
injectable use of the same drug and to have used non-sterile 
injection equipment in their first episode of drug use. 
Besides seropositivity for Bartonella, antibodies 
to Hantavirus and C. burnetii were also detected in a 
29-year-old and a 43-year-old PWID, respectively. These 
very low figures preclude any further assessment of putative 
associations between socio-demographic and behavioral 
variables and these outcomes. 
PWID characteristics and anti-Hantavirus antibodies
Anti-hantavirus point seroprevalence was 4.0% (12/300) 
(95% CI: 2.0%-7.0%). All individuals were male. The first 
illicit drug consumed was cocaine by another non-injectable 
route, with the exception of a 42-year-old individual, 
who had first injected amphetamine. The other subjects 
used cocaine as the first intravenous drug and 50% used 
previously used syringes.
DISCUSSION
This was the first Brazilian seroprevalence study on 
C. burnetii, Bartonella, and Hantavirus exposure among 
PWID.
The demographic profile of the PWID population, 
composed mainly of young male adults with a low degree of 
formal education,was similar to those observed in previous 
reports8,16,18,20,22,24,51,52. 
We found a relatively high seroprevalence of C. 
burnetii in this population (9.3%; 95% CI: 6.0%-13.0%), 
almost twice the frequency found among non-PWID 
populations. Lamas et al.53 found a seroprevalence of 
3.2% among HIV-positive patients from Rio de Janeiro, 
similar to the percentage (3.9%) found in the general 
population of Minas Gerais37. The greater susceptibility of 
PWID to infectious agents due to non-hygienic injection 
practices, immunosuppression and sharing of injection 
paraphernalia, may explain these findings. It is likely that 
the lack of a detailed assessment of specific risk factors 
for these infections (the overall study targeted HIV and 
viral hepatitis) did not help in the effort to find statistically 
significant associations between socio-demographic and 
behavioral variables and C. burnetii infection. 
In a Spanish study conducted in 590 PWID, a C. 
burnetii seroprevalence of 21.0% was reported21. This 
high frequency could be partially attributed to a lower 
definition of the IFA cutoff titer (1:16). If a cutoff point 
of 1:64 was used instead, as adopted in the present study, 
the reported seroprevalence would decrease to 14.6%, in 
agreement with our study since the confidence intervals 
overlap. A second study was carried out in Italy, where 
Boschini et al.16 detected a seroprevalence of 33% (using 
the complement fixation test) after two outbreaks that 
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occurred among residents in an agricultural community for 
the rehabilitation of drug users. It is pertinent to consider 
that, in this case, both methodological and epidemiological 
differences compromise comparative analyses.
There was no significant association between C. 
burnetti infection and socio-demographic variables. The 
seroprevalence of Bartonella infection was 1.0%, far 
below that observed in other Brazilian seroepidemiological 
studies, as reported by Lamas et al.53 in blood banks from 
Rio de Janeiro (24.0%) or among HIV-positive patients 
(38.4%).
Although there are no Brazilian studies on Bartonella 
seroprevalence among PWIDs, six international studies 
show a high prevalence of anti-Bartonella antibodies 
in this population. In European studies, the prevalence 
is significantly higher in this population, compared to 
people who do not inject drugs. In Sweden, a prevalence 
of 39.0% was found among 59 PWID, in contrast to the 
21.0% identified in the control group20; in Slovenia, these 
percentages were 43.0% vs. 25.0%, respectively25. In two 
Spanish studies, the seroreactivities for Bartonella among 
PWID were 13.7%24; and 24.2%22, whereas in other two 
American studies, the seroprevalences were 47.5% and 
37%, respectively8,18. The discrepancies in Bartonella 
seroprevalence in PWID found in our study and in other 
international studies could be partially explained by the 
global differences in the geographical distribution of 
Bartonella species. The highest reported seropositivities 
were observed against B. elizabethae, followed by B. 
quintana, both considered non-existent and/or rarely 
detected in Brazil. In our study, the B. henselae antigen 
was used. Therefore, it is reasonable to speculate that if 
other Bartonella species were included in our assay, a 
different seroprevalence could be observed. Unfortunately, 
commercial kits that include other species than B. henselae 
are not available. Moreover, our sample included a low 
frequency of homeless PWID and about half of the subjects 
did not report to have injected drugs in the last year, in 
contrast with other studies. This could be explained by the 
route transition hypothesis54.
Hantavirus seroprevalence was 4.0%, consistent with 
values found in other Brazilian studies, including 314 blood 
donors of Santa Catarina, a Southern State (4.4%)55, and 
1,063 individuals from the South and Southeast regions, 
including residents of rural areas, harbor employees and 
leptospirosis patients (3.0%)56. These samples are likely to 
contain the hantavirus genotype of Seoul, identified in the 
1980s in the North of Brazil, for which urban rats (Rattus 
norvegicus) are reservoirs57.
Although reference serological tests for the detection 
of Q fever (97.7% sensitivity and 100% specificity), 
bartonellosis (97.4% sensitivity and 100% specificity), and 
HPS/HCPS (97,2% sensitivity and 100% specificity) were 
used in the present study, we cannot rule out the possibility 
of cross-reactivity with other infectious agents; however, 
our results were based on IgG detection, which is less prone 
to low specificity than IgM detection. 
Additional studies on bartonellosis, including detection 
of a range of different bacterial species, would be valuable to 
assess comparable seroprevalences in different geographical 
regions. The high seroprevalence of C. burnetii among 
PWID must be highlighted and reinforces the need for 
further prospective studies, including serological and 
molecular analyses, to confirm these first findings and 
to allow a better understanding of the importance of Q 
fever among this population. This paper highlights the 
findings of a targeted surveillance of a highly vulnerable 
population. This study has been carried outwith the double 
purpose of identifying “sentinel populations”, as well as the 
effort to discern the putative bridging between vulnerable 
populations with other populations or the general population 
at large.
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